3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
20
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Sarcoma
4
Neoplasms
4
Urinary Bladder Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Merkel Cell
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Cutaneous
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Mesothelioma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
27
Nivolumab
20
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Carboplatin
4
fludarabine
3
avelumab
3
Pemetrexed
3
Interleukin-2
3
tislelizumab
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Cisplatin
2
veliparib
1
toripalimab
1
spartalizumab
1
sotigalimab
1
sonidegib
1
sargramostim
1
regorafenib
1
poly ICLC
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
poly ICLC
×
Dermatologic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled